VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...

A recent study suggests that liraglutide, a drug similar to Ozempic, may reduce migraine frequency in obese individuals with ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

The Obesity Drug Development Summit Europe is your perfect platform to be in a prime position to be at the forefront of this ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

A new study found that Ozempic's main ingredient may treat people with type 1 diabetes, control blood sugar, and lose weight.

A drug that outperforms placebo in helping people to lose weight is one of a growing number of next-generation obesity drugs being produced in China. At first, Chinese pharmaceutical companies rushed ...

Obesity remains one of the greatest health challenges worldwide, leading to diabetes, heart disease, and increased healthcare ...